|Year : 2004 | Volume
| Issue : 2 | Page : 75-80
Extended spectrum -lactamases (ESBL) - An emerging threat to clinical therapeutics
U Chaudhary, R Aggarwal
Microbiology Department, Postgraduate Institute of Medical Sciences, Rohtak - 124 001, Haryana, India
Microbiology Department, Postgraduate Institute of Medical Sciences, Rohtak - 124 001, Haryana, India
Extended spectrum -lactamases (ESBLs) are plasmid mediated, TEM and SHV derived enzymes, first isolated in Western Europe in mid 1980s, most commonly in Klebsiella spp., followed by Escherichia coli. These enzymes are capable of hydrolyzing broad spectrum cephalosporins and monobactams but inactive against cephamycins and imipenem. In addition, ESBL producing organisms exhibit coresistance to many other classes of antibiotics resulting in limitation of therapeutic option. Several risk factors have been suggested. A variety of classification schemes have been developed. Recently, Bush-Jacoby-Medeiros scheme integrated functional and molecular characteristics. ESBLs have serine at their active site and attack the amide bond in the lactam ring of antibiotics causing their hydrolysis. Because of inocolum effect and substrate specificity their detection is a major challenge. Two indicators of ESBLs are eight fold reduction in MIC and potentiation of the inhibitor zone of third generation cephalosporin in the presence of clavulanic acid. Incidence of these organisms is being continuously increasing through out the world with limited treatment alternatives. It becomes necessary to know the prevalence of these organisms and to formulate treatment policy. Moreover, restricted use of the third generation cephalosporins lead to withdrawal of selective pressure and use of lactam and -lactamase inhibitor combinations may exert reverse mutation on these enzymes.
|How to cite this article:|
Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004;22:75-80
|How to cite this URL:|
Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol [serial online] 2004 [cited 2017 Jan 18];22:75-80. Available from: http://www.ijmm.org/text.asp?2004/22/2/75/8076
Resistant bacteria are emerging world wide as a threat to the favourable outcome of common infections in community and hospital settings. b-lactamase production by several gram negative and gram positive organisms is perhaps the most important single mechanism of resistance to penicillins and cephalosporins. In the past it was believed that cephalosporins were relatively immune to attack by b-lactamases. It was surprising to find cephalosporin resistant Klebsiella spp. among the clinical isolates. The mechanism of this resistance was production of extended spectrum b-lactamases (ESBLs).
The ESBL enzymes are plasmid - mediated enzymes capable of hydrolyzing and inactivating a wide variety of b lactams, including third generation cephalosporins, penicillins and aztreonam. These enzymes are the result of mutations of TEM-1 and TEM-2 and SHV-I. All of these b-lactamase enzymes are commonly found in the Enterobacteriaceae family. Normally, TEM-1, TEM-2 and SHV-1 enzymes confer high level resistance to early pencillins and low level resistance to first generation cephalosporins. Widespread use of third generation cephalosporins and aztreonam is believed to be the major cause of the mutations in these enzymes that has led to the emergence of the ESBLs. These enzymes mediate resistance to cefotaxime, ceftazidime and other broad spectrum cephalosporins and to monobactams such as aztreonam, but have no detectable activity against cephamycins and imipenem. Because, of their greatly extended substrate range these enzymes were called extended spectrum b-lactamases.
The first ESBL isolates were discovered in Western Europe in mid 1980s and subsequently in the US in the late 1980s. The resistant organisms are now a worldwide problem. They can be found in a variety of Entrerobacteriaceae species, however, the majority of ESBL producing strains are K. pneumoniae, K. oxytoca and E.coli. Other organisms reported to harbour ESBLs include Enterobacter spp., Salmonella More Details spp., Morganella morganii, Proteus mirabilis, Serratia marcescens and Pseudomonas aeruginosa. However, the frequency of ESBL production in these organisms is low.
Major risk factors for colonization or infection with ESBL producing organisms are long term antibiotic exposure, prolonged ICU stay, nursing home residency, severe illness, residence in an institution with high rates of ceftazidime and other third generation cephalosporin use and instrumentation or catheterisation.
| ~ Evolution and Dissemination of b-Lactamases|| |
Fifty years ago the antibiotic era began with the discovery of penicillin. With in a few years of introduction of penicillin into clinical use, penicillinase producing Staphylococcus aureus started to proliferate in hospitals. To overcome this problem, penicillinase resistant penicillins came into picture. Shortly afterward, the broad spectrum penicillins and first generation cephalosporins were introduced. They remained a first line of defense against microbes for over 20 years, before resistance due to b-lactamases produced by gram negative bacilli became a serious problem.
To counter this threat, the pharmaceutical industry marketed six novel classes of b lactam antibiotics (cephamycins, oxyimino cephalosporins, carbapenems, monobactams and clavam and penicillianic acid sulfone inhibitors) within a relatively short span of 7-8 years. Although, novel b-lactamases had emerged gradually after the introduction of new b lactam agents, their number and variety accelerated at an alarming rate [Table - 1]., More than 170 b-lactamases have been recognised. Their growth spurt shows no signs of slowing down.
| ~ Classification Schemes|| |
Various classification schemes have been proposed by many researchers. Classification of Sawai et al in 1968 was based on response to antisera. Richmond and Sykes scheme in 1973 was on the basis of substrate profile. Extension of the Richmond and Sykes scheme by Sykes and Mathew in 1976 was based on differentiation by isoelectric focussing. In the scheme proposed by Mitsuhashi and Inoue in 1981, the category “cefuroxime hydrolyzing b-lactamases” was added to “penicillinase and cephalosporinase” classification. The groupings proposed by Bush in 1989 was based on correlation of substrate and inhibitory properties with molecular structure.
However, the number and variety of enzymes have proliferated beyond the boundaries of the scheme. A more modern scheme based on molecular structure classification was proposed by Ambler includes, of necessity, only those enzymes that have been characterized.
Recently a new classification scheme has been developed to integrate functional and molecular characteristics. The Bush-Jacoby-Medeiros scheme puts 178 b-lactamases from naturally occurring bacterial isolates into four groups based on substrate and inhibitor profiles [Table - 2].
| ~ Structure of b-Lactamase and Mechanism of Action|| |
All ESBLs have serine at their active sites except for a small (but rapidly growing) group of metallo b-lactamases belonging to class B. They share several highly conserved amino acid sequences with penicillin binding proteins (PBPs).
b-lactamases attack the amide bond in the b lactam ring of penicillins and cephalosporins, with subsequent production of pencillinoic acid and cephalosporic acid, respectively, ultimately rendering the compounds antibacterially inactive.
Plasmids responsible for ESBL production tend to be large (80 Kb or more in size) and carry resistance to several agents, an important limitation in the design of treatment alternatives. The most frequent coresistances found in ESBL producing organisms are aminoglycosides, fluoroquinolones, tetracyclines, chloramphenicol and sulfamethoxazole-trimethoprim.
Except for one brief report, none of these enzymes have been shown to be transposable. The usual transmissibility of the responsible plasmids, however, allows resistance to spread readily to other pathogens so that extended spectrum enzymes have been found in nearly all species of Enterobacteriaceae. Reports of ESBLs in P. mirabilis have been relatively rare. In this species, it may be due to low frequency of plasmid conjugation.
Since, ESBL production is usually plasmid mediated it is possible for one specimen to contain both ESBL producing and non ESBL producing cells of the same species. This suggests that for optimal detection, several colonies must be tested from a primary culture plate.
| ~ Problems in Detection|| |
Identifying organisms that are ESBL producers is a major challenge for the clinical microbiology laboratory. Due to the variable affinity of these enzymes for different substrates and inoculum effect, some ESBL isolates may appear susceptible to a third generation cephalosporin in vitro. However, treatment of infections due to an ESBL producing organism with third generation cephalosporins may result in clinical failure if infection is outside the urinary tract.
Cefpodoxime and ceftazidime have been proposed as indicators of ESBL production as compared to cefotaxime and ceftriaxone. Hence, an institution where only cefotaxime and ceftriaxone are used in the routine sensitivity testing panel may have difficulty in detecting ESBLs.
These enzymes can be induced by certain antibiotics, amino acids or body fluids. Organisms possessing genes for inducible b- lactamases show false susceptibility if tested in the uninduced state.
For ESBL producing bacteria there is a dramatic rise of MIC for extended spectrum cephalosporins as the inoculum is increased beyond that used in routine susceptibility. Same isolates test susceptible at the standard inoculum of 10 CFU/mL but resistant at an inoculum of 10 CFU/mL. Therefore, they may be reported as false sensitive if tested by routine methods.
Sensitivity breakpoints of MIC as designated in the National Committee for Clinical Laboratory Standards (NCCLS) guidelines for Klebsiella and E. coli against cefotaxime, ceftriaxone and ceftazidime are less than or equal to 8 mg/mL. Some ESBL producing organisms may have increased MIC against these agents compared with those of non-ESBL isolates. However, the increased MIC is still lower than the cut off value for susceptibility.
Latest guidelines by NCCLS recommend screening Klebsiella spp. and E. coli isolates with a MIC greater than or equal to 2 mg/mL against cefpodoxime, ceftazidime, aztreonam, cefotaxime, or ceftriaxone as potential ESBL producers. Two indicators of ESBLs are an 8 fold reduction in MIC in the presence of clavulanic acid when using the broth dilution and the potentiation of the inhibitor zone by clavulanic acid (>5 mm increase in diameter of inhibition zone) when using disc diffusion method. These methods, though useful, may not detect those ESBLs that are poorly inhibited by b-lactamase inhibitors.
Two recent studies evaluated the ability of clinical laboratories to detect and report the presence of ESBLs. A survey in Connecticut found that 21% of laboratories fail to detect ESBL producing isolates. A proficiency testing project for clinical laboratories participating in the National Nosocomial Infections Surveillance System indicated that as many as 58% laboratories failed to detect and report ESBL isolates correctly. These data suggest that improvements in the ability of clinical laboratories to detect ESBL are needed.
| ~ Methods of Detection|| |
Several tests have been developed to confirm the presence of ESBLs.
Double disc synergy test
In this test discs of third generation cephalosporins and augmentin are kept 30 mm apart from center to center on inoculated Mueller-Hinton Agar (MHA). A clear extension of the edge of the inhibition zone of cephalosporin towards augmentin disc is interpreted as positive for ESBL production.
Three dimensional test
This test provides the advantage of simultaneous determination of antibiotic susceptibility and b-lactamase substrate profile. Inoculum produced in this method contains between 109 and 1010 CFU/mL of cells that actively produce b-lactamase. Two types of inocula are prepared one disc diffusion test inoculum (optical density equal to that of 0.5 McFarland standard) and a three dimensional inoculum (contain between 109 and 1010 CFU of cells). Plate is inoculated by disc diffusion procedure. A circular slit is cut on the agar 4mm inside the position at which the antibiotic discs are placed. Conventional (two dimensional) disc diffusion susceptibility test results are measured according to the recommendations of NCCLS. Distortion or discontinuity in the circular inhibition zone is interpreted as positive for ESBL production.
Inhibitor potentiated disc diffusion test
Cephalosporin disc is placed on clavulanate containing and with out clavulanate containing MHA plates. More than10 mm increase in the zone of inhibition on the clavulanate containing MHA plate indicates ESBL production.
Disk approximation test
Cefoxitin (inducer) disc is placed at a distance of 2.5 cm from cephalosporin disc. Production of inducible b-lactamase is indicated by flattening of the zone of inhibition of the cephalosporin disc towards inducer disc by >1 mm.
MIC reduction test
An 8 fold reduction in the MIC of cephalosporin in the presence of clavulanic acid indicates production of ESBL.
Vitek ESBL Test
Four wells containing cards are inoculated. A predetermined reduction in growth of cephalosporin well containing clavulanic acid; when compared with the level of growth in well with cephalosporin alone indicates presence of ESBL.
The E test ESBL strip carries two gradients, on the one end, ceftazidime and on the opposite end ceftazidime plus clavulanic acid. MIC is interpreted as the point of intersection of the inhibition ellipse with the E test strip edge. Ratio of ceftazidime MIC and ceftazidime clavulanic acid MIC equal to or greater than 8 indicates the presence of ESBL.
| ~ Treatment|| |
Of all the available b lactams carbapenems are the most effective and reliable as they are highly resistant to the hydrolytic activity of all ESBL enzymes, due to the trans-6 hydroxy ethyl group. Meropenem is the most active with MICs generally lower than those of imipenem (0.03-0.12mg/mL vs 0.06-0.5mg/mL). Several new carbapenems, ertapenem and faropenem are being studied in the various phases of clinical trials.
Some infections due to organisms testing resistant to ceftazidime but susceptible to cefotaxime or ceftriaxone have responded to treatment with these alternate cephalosporins. However, MICs of these agents rise dramatically as the inoculum is increased.
A few b lactams, 7 a methoxy cephalosporins such as cefoxitin, cefmetazole, cefotetan and latamoxef are often effective in the treatment of infections caused by enzyme producing bacteria. However, cephamycins should be used with caution because of the relative ease with which clinical strains decrease expression of outer membrane proteins.
Although ESBL activity is inhibited by clavulanic acid the only infections that may be treated safely with b lactam/b-lactamase inhibitor combination are those involving the urinary tract. In this instance, b- lactamase inhibitor concentration is high enough to counteract the hydrolytic activity of ESBLs.
By inhibiting ESBL, b-lactamase inhibitors appear to impair the emergence and spread of Klebsiella carrying resistance plasmids. Furthermore, administration of inhibitors may exert in vitro pressure on ESBL, thereby facilitating their reverse mutation to less harmful enzymes.
Clavulanic acid appears more efficient than sulbactam, it takes about eight times more sulbactam to obtain a protection similar to that given by clavulanic acid.
Non b lactam antimicrobial agents (aminoglycosides, fluoroquinolones) may be beneficial, however, coresistance rates against these agents are frequent.
| ~ Prevention|| |
Institutions with endemic ESBL-producing organisms need to determine whether there is a high rate of cephalosporin use, especially third generation cephalosporins. Several studies have shown that by limiting the use of these agents alone or in combination with infection control measures, the frequency of ESBL isolates can be reduced substantially. Educational programs for medical staff to increase awareness also should be developed.
| ~ Conclusion|| |
ESBL producing organisms pose a major problem for clinical therapeutics. The incidence of ESBL producing strains among clinical isolates has been steadily increasing over the past few years resulting in limitation of therapeutic options.
Initially restricted to hospital acquired infections, they have also been isolated from infections in outpatients. Major outbreaks involving ESBL strains have been reported from all over the world, thus making them emerging pathogens.
The routine susceptibility tests done by clinical laboratories fail to detect ESBL positive strains and can erroneously detect isolates sometimes to be sensitive to any of the broad spectrum cephalosporin like cefotaxime, ceftazidime,ceftriaxone.
With the spread of ESBL producing strains in hospitals all over the world, it is necessary to know the prevalence of ESBL positive strains in a hospital so as to formulate a policy of empirical therapy in high risk units where infections due to resistant organisms is much higher. Equally, important is the information on an isolate from a patient to avoid misuse of extended spectrum cephalosporins, which still remain an important component of antimicrobial therapy in high risk wards.
A knowledge of resistance pattern of bacterial strains in a geographical area will help to guide the appropriate and judicious antibiotic use. There is possibility that the restricted use can lead to the withdrawal of selective pressure and resistant bacteria will no longer have survival advantage in such settings.
| ~ References|| |
|1.||Ayyagari A, Bhargava A. -lactamases and their clinical significance (A mini review). Hosp Today 2001;6(10):1-6. |
|2.||Nathisuwan S, Burgess DS, Lewis II JS. ESBLs : Epidemiology, Detection and Treatment. Pharmacotherapy 2001;21(8): 920-928. |
|3.||Sirot D. Extended - spectrum plasmid - mediated -lactmases. J Antimicrob Chemother 1995;36(Suppl A):19-34. |
|4.||Medeiros AA. Evolution and dissemination of -lactamases acclerated by generations of -lactam antibiotics. Clin Infect Dis 1997;24(Suppl 1):S19-45. |
|5.||Nordmann P. Trends in -lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998;27(Suppl 1): S100-S1006. |
|6.||Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-1233. |
|7.||Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn WC Jr, editors. Antimicrobial suceptibility testing. In : Color Atlas And Textbook of Diagnostic Microbiology. 5th ed. (Lippincott, Philadelphia) 1997; 785-856. |
|8.||Jacoby GA, Medeiros AA. More extended spectrum -lactamases. Antimicrob Agents Chemother 1991;35:1697-1704. |
|9.||Coudron PE, Moland ES, Sanders CC. Occurrence and detection of ESBL in members of the family Enterobacteriacieae at a Veterans Medical Center : Seek and you may find. J Clin Microbiol 1997;35:2593-2597. |
|10.||Revathi G, Singh S. Detection of Expanded spectrum cephalosporin resistance due to inducible lactamases in hospital isolates. Indian J Med Microbiol 1997;15(3):113-115. |
|11.||Emery CL, Weymouth LA. Detection and clinical significance of ES Ls in a tertiary - care medical center. J Clin Microbiol 1997;35:2061-2067. |
|12.||Jarlier V, Nicolas MH, Fournier G, Philippon A. ESBLs conferring transferable resistance to newer -lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988;10:867-878. |
|13.||Thomson KS, Sanders CC. Detection of ESBLs in members of the family Enterobacteriaceae. Comparison of the double disk and three-dimensional test. Antimicrob Agents Chemother 1992;36:1877-1882. |
|14.||Ho PL, Chow KH, Yuen KY, Ng WS, Chau PY. Comparison of novel, inhibitor potentiated disc diffusion test with other methods for the detection of ESBL in E.coli and K. pneumoniae. J Antimicrob Chemther 1998;42:49-54. |
|15.||Sanders CC, Barry AL, Washington JA, Shubert C, Moland ES, Traczewski MM, Knapp C, Mulder R. Detection of ESBL producing members of the family Enterobacteriaceae with the Vitek ES L test. J Clin Microbiol 1996;34:2997-3001. |
|16.||Vercauteren E, Descheemaeker P, Leven M, Sanders CC, Goossens H. Comparison of screening methods for detection of ESBL and their prevalence among blood isolates of E.coli and Klebsiella spp. in a Belgian teaching hospital. J Clin Microbiol 1997;35:2191-2197. |
|17.||Piroth L, Aube H, Doise JM, Martin MV. Spread of ESBL - producing K. pneumoniae. Are -lactamase inhibitors of therapeutic value? Clin Infect Dis 1998;27:76-80. |
|18.||Sirot J, Chanal C, Petil A, Sirot D, Labia R, Gerbaud G. K. pneumoniae and other Enterobacteriaceae producing novel plasmid mediated -lactamases markedly active against third-generation cephalosporin: epidemiologic studies. Rev Infect Dis 1988;10:850-859. |
|19.||Ananthkrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of ESBL producers among surgical wound infections and burns patients in JIPMER. Indian J Med Microbiol 2000;18(4):160-165. |
|20.||Mathur P, Kapil A, Das B, Dhawan B. Prevalence of ESBL producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002;115:153-157. |